Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 13/20 | 0.53 |
| ▸ | MMP1 | P03956 | 8/20 | 0.53 |
| ▸ | MMP3 | P08254 | 8/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | MMP7 | P09237 | 3/20 | 0.50 |
| ▸ | IL1RN | P18510 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212676 | 0.88 | BIRC2 (0.53) | BIRC2TSHRMMP2MMP1ERAP2 | |
| SCHEMBL21294072 | 0.88 | MME (0.58) | MMP2MMP1MMP3MMP7 | |
| SCHEMBL21294071 | 0.88 | MME (0.58) | MMP2MMP1MMP3MMP7 | |
| SCHEMBL30759487 | 0.83 | ERAP2 (0.67) | BIRC2TSHRERAP2LNPEPERAP1 | |
| SCHEMBL2337076 | 0.82 | HDAC1 (0.66) | NPSR1 | |
| SCHEMBL27910970 | 0.82 | HDAC1 (0.66) | NPSR1 | |
| SCHEMBL14472130 | 0.82 | HDAC1 (0.66) | NPSR1 | |
| SCHEMBL18220518 | 0.82 | HDAC1 (0.66) | NPSR1 | |
| SCHEMBL14472192 | 0.82 | HDAC1 (0.66) | NPSR1 | |
| Hydrochloric Acid SCHEMBL29094270 | 0.82 | ESR1 (0.52) | BIRC2TSHRERAP2LNPEPERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11285119-B2 | Anti-inflammatory composition | NEOPHARM CO., LTD. (KR) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285119-B2 | Anti-inflammatory composition | TNF, CUTA, IL6 | BIRC2 1883/4885TSHR 4764/4885MMP2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.